0001589150 false 0001589150 2024-02-07 2024-02-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 7, 2024

REGEN BIOPHARMA, INC.

(Exact name of small business issuer as specified in its charter)

 

Nevada 45-5192997
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

 

Commission File No. 333-191725

  

4700 Spring Street, St 304, La Mesa, California 91942

(Address of Principal Executive Offices)

 

(619) 722 5505

(Issuer’s telephone number)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class Trading Symbol(s) Name of each exchange on which registered
  None  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 1 

 

Item 8.01 Other Events.

On February 7, 2024 Regen Biopharma, Inc. filed a provisional patent application with the United States Patent and Trademark Office covering compositions of matter, protocols and treatment means for accelerating hematopoietic reconstitution after an insult or chronic pathology by administration of stem cell derived endothelial progenitor cells or endothelial cells

 2 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  REGEN BIOPHARMA, INC.
   

Dated: February 9, 2024

 By: /s/ David Koos

 

 3 

 

 

v3.24.0.1
Cover
Feb. 07, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 07, 2024
Entity File Number 333-191725
Entity Registrant Name REGEN BIOPHARMA, INC.
Entity Central Index Key 0001589150
Entity Tax Identification Number 45-5192997
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 4700 Spring Street
Entity Address, Address Line Two  St 304
Entity Address, City or Town  La Mesa
Entity Address, State or Province CA
Entity Address, Postal Zip Code 91942
City Area Code 619
Local Phone Number 722 5505
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Regen Biopharma (PK) (USOTC:RGBPP)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Regen Biopharma (PK) Charts.
Regen Biopharma (PK) (USOTC:RGBPP)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Regen Biopharma (PK) Charts.